Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial)

Autor: Eugene Braunwald, Fahad AlKhalfan, Alexei N. Plotnikov, Tarek Nafee, Gerald Chi, Megan K. Yee, C. Michael Gibson, Arzu Kalayci

Publikováno v: The American Journal of Cardiology. 125:661-669

An elevated white blood cell (WBC) count is associated with an increased risk of ischemic events among acute coronary syndrome (ACS) patients, but the association between WBC count and bleeding in ACS patients is not well established. The aim of this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed148e89fb72786ed95676ea7bac2a52
https://doi.org/10.1016/j.amjcard.2019.12.007

Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51

Autor: Eugene Braunwald, Paul Burton, Alexei N. Plotnikov, Yazan Daaboul, C. Michael Gibson, Megan K. Yee, William J. Gibson, Serge Korjian

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Background A residual risk of ischemic events following an acute coronary syndrome (ACS) remains despite antiplatelet therapy. The addition of an antithrombin as part of a “dual pathway” approach may further improve outcomes as thrombin generatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8df33b2504fb0beb25b4244935c3144e
https://doi.org/10.1161/jaha.118.009451

Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial

Autor: Alexei N. Plotnikov, Yazan Daaboul, C. Michael Gibson, Purva Jain, Serge Korjian, Freek W.A. Verheugt, Eugene Braunwald, Paul Burton, Christoph Bode, Michal Tendera

Publikováno v: European Heart Journal Acute Cardiovascular Care, 8, 186-193
European Heart Journal Acute Cardiovascular Care, 8, 2, pp. 186-193

Background: Despite dual antiplatelet therapy, persistent thrombin generation and thrombin-mediated platelet activation account in part for the residual risk of atherothrombotic disease among patients with prior acute coronary syndrome (ACS). Inhibit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17aba72bee8755b83465974258056b01
https://pubmed.ncbi.nlm.nih.gov/29249166

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1):a double-blind, multicentre, randomised trial

Autor: M. Cecilia Bahit, Robert C. Welsh, P. Gabriel Steg, Alexei N. Plotnikov, Matthew T. Roe, Jennifer White, Thomas J. Povsic, Gilles Montalescot, C. Michael Gibson, Christoph Bode, Jose C. Nicolau, Jan H. Cornel, John Strony, Marc J. Claeys, Stefan James, Michal Tendera, E. Magnus Ohman, Diego Ardissino, Ümit Güray, Héctor Bueno, Shinya Goto, Frank W. Rockhold, Xiang Sun, Róbert Gábor Kiss, Steen Husted, Duk-Woo Park, Hardi Mundl

Publikováno v: Ohman, E M, Roe, M T, Steg, P G, James, S K, Povsic, T J, White, J, Rockhold, F, Plotnikov, A, Mundl, H, Strony, J, Sun, X, Husted, S, Tendera, M, Montalescot, G, Cecilia Bahit, M, Ardissino, D, Bueno, H, Claeys, M J, Nicolau, J C, Cornel, J H, Goto, S, Kiss, R G, Guray, U, Park, D-W, Bode, C, Welsh, R C & Gibson, C M 2017, ' Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1) : a double-blind, multicentre, randomised trial ', Lancet, vol. 389, no. 10081, pp. 1799-1808 . https://doi.org/10.1016/S0140-6736(17)30751-1
The lancet : international edition

Summary Background Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::346f2b63d42f88890853093da76ddb88
https://pure.au.dk/portal/da/publications/clinically-significant-bleeding-with-lowdose-rivaroxaban-versus-aspirin-in-addition-to-p2y12-inhibition-in-acute-coronary-syndromes-geminiacs1(f062a451-312b-4110-8ac5-a3fca1ff024a).html

P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes

Autor: Stefan James, P. Gabriel Steg, Matthew T. Roe, Thomas J. Povsic, Robert C. Welsh, Jennifer White, Jose C. Nicolau, Alexei N. Plotnikov, Gilles Montalescot, Christoph Bode, Hardi Mundl, Jan H. Cornel, Frank W. Rockhold, E. Magnus Ohman, C. Michael Gibson

Publikováno v: JAMA Cardiology, 4, 680-684
JAMA Cardiol
JAMA Cardiology, 4, 7, pp. 680-684

Contains fulltext : 215293.pdf (Publisher’s version ) (Closed access) Importance: Physician behavior in response to knowledge of a patient's CYP2C19 clopidogrel metabolizer status is unknown. Objective: To investigate the association of mandatory r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd8db8fc6283f9bc8e00815039f00aa
https://doi.org/10.1001/jamacardio.2019.1510